Other languages Clene Inc.

Equities

CLNN

US1856341029

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
0.37 ^USD	-4.05%		-4.27%	+24.75%

May. 08	Earnings Flash (CLNN) CLENE Reports Q1 Revenue $73M	MT
Apr. 16	Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	Apr. 16
Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8	Mar. 15
Clene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13
Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs	Feb. 22
Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial	Jan. 08
US FDA finds Clene's trial data for ALS drug to be insufficient	Dec. 21
Clene Inc. and Clene Nanomedicine Inc. Announce Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases	Dec. 14
Clene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Sector Update: Health Care Stocks Advancing Late Afternoon	23-10-05
Sector Update: Health Care	23-10-05
Clene Shares Jump After Being Awarded $45.1 Million Government Grant for Investigational ALS Drug	23-10-05
Clene Awarded $45.1 Million Government Grant to Fund EAP for Investigational ALS Drug	23-10-05
Clene Files for Potential Secondary Offering of Up to 3 Million Common Shares	23-09-25
Clene Inc. Announces Executive Changes	23-09-19
Clene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Insider Buy: Clene	23-06-27
Clene Announces Publication of Phase 2 CNM-Au8Â® Clinical Data for the Treatment of ALS in LANCETâ€™s eClinicalMedicine	23-06-26
Insider Buy: Clene	23-06-20
Insider Buy: Clene	23-06-20
MÄRKTE USA/Leichte Verluste am Ende einer starken Woche	23-06-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Clene Inc.

Equities

CLNN

US1856341029

Other languages

Filters